The results of Eftekhari et al. [68] revealed that combined therapy based on docetaxel and liraglutide (GLP-1 receptor agonist) may enhance the chemotherapy response in metastatic prostate cancer (use of a lower dose with maintained efficacy and reduced toxicity). The gene discussed is GLP1R; the disease is metastatic prostate carcinoma.